{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:34Z","timestamp":1791874714211,"version":"4.3.4"},"reference-count":560,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Somatostatin is a peptide that plays a variety of roles such as neurotransmitter and endocrine regulator; its actions as a cell regulator in various tissues of the human body are represented mainly by inhibitory effects, and it shows potent activity despite its physiological low concentrations. Somatostatin binds to specific receptors, called somatostatin receptors (SSTRs), which have different tissue distributions and associated signaling pathways. The expression of SSTRs can be altered in various conditions, including tumors; therefore, they can be used as biomarkers for cancer cell susceptibility to certain pharmacological agents and can provide prognostic information regarding disease evolution. Moreover, based on the affinity of somatostatin analogs for the different types of SSTRs, the therapeutic range includes conditions such as tumors, acromegaly, post-prandial hypotension, hyperinsulinism, and many more. On the other hand, a number of somatostatin antagonists may prove useful in certain medical settings, based on their differential affinity for SSTRs. The aim of this review is to present in detail the principal characteristics of all five SSTRs and to provide an overview of the associated therapeutic potential in neoplasias.<\/jats:p>","DOI":"10.3390\/cimb46090578","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T02:25:49Z","timestamp":1725416749000},"page":"9721-9759","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias"],"prefix":"10.3390","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8319-7464","authenticated-orcid":false,"given":"Argyrios","family":"Periferakis","sequence":"first","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Elkyda, Research & Education Centre of Charismatheia, 17675 Athens, Greece"},{"name":"Akadimia of Ancient Greek and Traditional Chinese Medicine, 16675 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-4210","authenticated-orcid":false,"given":"Georgios","family":"Tsigas","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5827-3181","authenticated-orcid":false,"given":"Aristodemos-Theodoros","family":"Periferakis","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Elkyda, Research & Education Centre of Charismatheia, 17675 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8085-2663","authenticated-orcid":false,"given":"Carla Mihaela","family":"Tone","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7838-7547","authenticated-orcid":false,"given":"Daria Alexandra","family":"Hemes","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8919-2840","authenticated-orcid":false,"given":"Konstantinos","family":"Periferakis","sequence":"additional","affiliation":[{"name":"Akadimia of Ancient Greek and Traditional Chinese Medicine, 16675 Athens, Greece"},{"name":"Pan-Hellenic Organization of Educational Programs, 17236 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7388-1466","authenticated-orcid":false,"given":"Lamprini","family":"Troumpata","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7282-5189","authenticated-orcid":false,"given":"Ioana Anca","family":"Badarau","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7676-6393","authenticated-orcid":false,"given":"Cristian","family":"Scheau","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Radiology and Medical Imaging, \u201cFoisor\u201d Clinical Hospital of Orthopaedics, Traumatology and Osteoarticular TB, 030167 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4200-3069","authenticated-orcid":false,"given":"Ana","family":"Caruntu","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, The \u201cCarol Davila\u201d Central Military Emergency Hospital, 010825 Bucharest, Romania"},{"name":"Department of Oral and Maxillofacial Surgery, Faculty of Dental Medicine, \u201cTitu Maiorescu\u201d University, 031593 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca","family":"Savulescu-Fiedler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Internal Medicine and Cardiology, Coltea Clinical Hospital, 030167 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-7965","authenticated-orcid":false,"given":"Constantin","family":"Caruntu","sequence":"additional","affiliation":[{"name":"Department of Physiology, The \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Department of Dermatology, \u201cProf. N.C. Paulescu\u201d National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-2628","authenticated-orcid":false,"given":"Andreea-Elena","family":"Scheau","sequence":"additional","affiliation":[{"name":"Department of Radiology and Medical Imaging, Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1073\/pnas.77.11.6827","article-title":"Primary structure of ovine hypothalamic somatostatin-28 and somatostatin-25","volume":"77","author":"Esch","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0014-5793(80)81310-X","article-title":"N-terminally extended somatostatin: The primary structure of somatostatin-28","volume":"109","author":"Pradayrol","year":"1980","journal-title":"FEBS Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1126\/science.6142531","article-title":"Sequence of the human somatostatin I gene","volume":"224","author":"Shen","year":"1984","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature","volume":"70","author":"Tulipano","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJM198312223092506","article-title":"Somatostatin (second of two parts)","volume":"309","author":"Reichlin","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000180967","article-title":"Somatostatin: A Historical Perspective","volume":"29","author":"Hall","year":"2008","journal-title":"Horm. Res."},{"key":"ref_9","first-page":"427","article-title":"Molecular biology of somatostatin receptors","volume":"16","author":"Reisine","year":"1995","journal-title":"Endocr. Rev."},{"key":"ref_10","unstructured":"O\u2019Toole, T.J., and Sharma, S. (2024). Physiology, Somatostatin. StatPearls, StatPearls Publishing LLC."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/bmj.295.6593.288","article-title":"Somatostatin","volume":"295","author":"Bloom","year":"1987","journal-title":"Br. Med. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.mce.2007.12.009","article-title":"Physiology and pathology of somatostatin in the mammalian retina: A current view","volume":"286","author":"Cervia","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Scheau, C., Draghici, C., Ilie, M.A., Lupu, M., Solomon, I., Tampa, M., Georgescu, S.R., Caruntu, A., Constantin, C., and Neagu, M. (2021). Neuroendocrine Factors in Melanoma Pathogenesis. Cancers, 13.","DOI":"10.3390\/cancers13092277"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gut.35.3_Suppl.S1","article-title":"Somatostatin and somatostatin analogues: Pharmacokinetics and pharmacodynamic effects","volume":"35","author":"Harris","year":"1994","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: From signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Shamsi, B.H., Chatoo, M., Xu, X.K., Xu, X., and Chen, X.Q. (2021). Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.652363"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109622","DOI":"10.1016\/j.neuropharm.2023.109622","article-title":"Somatostatin signaling modulates binge drinking behavior via the central nucleus of the amygdala","volume":"237","author":"Robinson","year":"2023","journal-title":"Neuropharmacology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e2216820120","DOI":"10.1073\/pnas.2216820120","article-title":"Somatostatin regulates central clock function and circadian responses to light","volume":"120","author":"Joye","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","first-page":"427","article-title":"Somatostatin as a neurotrophic factor. Which receptor\/second messenger transduction system is involved?","volume":"5","author":"Schwartz","year":"1998","journal-title":"Perspect. Dev. Neurobiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: Current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1840069","DOI":"10.1155\/2021\/1840069","article-title":"Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma","volume":"2021","author":"Periferakis","year":"2021","journal-title":"Anal. Cell. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34","DOI":"10.20517\/2394-5079.2018.33","article-title":"Somatostatin in hepatocellular carcinoma: Experimental and therapeutic implications","volume":"4","author":"Kouroumalis","year":"2018","journal-title":"Hepatoma Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s00259-024-06639-4","article-title":"Gallium-68 labeled somatostatin receptor antagonist PET\/CT in over 500 patients with neuroendocrine neoplasms: Experience from a single center in China","volume":"51","author":"Liu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116017","DOI":"10.1016\/j.ejmech.2023.116017","article-title":"Discovery and exploration of novel somatostatin receptor subtype 5 (SSTR5) antagonists for the treatment of cholesterol gallstones","volume":"264","author":"Han","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_25","first-page":"1","article-title":"International Union of Pharmacology recommendations for nomenclature of new receptor subtypes","volume":"48","author":"Vanhoutte","year":"1996","journal-title":"Pharmacol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0165-6147(00)88988-9","article-title":"Classification and nomenclature of somatostatin receptors","volume":"16","author":"Hoyer","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1073\/pnas.89.1.251","article-title":"Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney","volume":"89","author":"Yamada","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","first-page":"259","article-title":"Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies","volume":"94","author":"Schulz","year":"2000","journal-title":"J. Physiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/s-2007-976540","article-title":"Characterization and transcriptional regulation of the human somatostatin receptor subtype 1 gene","volume":"39","author":"Redmann","year":"2007","journal-title":"Horm. Metab. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2982.2007.00931.x","article-title":"Effect of intestinal inflammation on the cell-specific expression of somatostatin receptor subtypes in the murine ileum","volume":"19","author":"Lantermann","year":"2007","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2013.02.001","article-title":"Reevaluation of sst1 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-7","volume":"183","author":"Lupp","year":"2013","journal-title":"Regul. Pept."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1073\/pnas.90.9.4196","article-title":"Cloning and characterization of a fourth human somatostatin receptor","volume":"90","author":"Rohrer","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1210\/jc.2008-1063","article-title":"Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1","volume":"93","author":"Fischer","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3803\/EnM.2019.34.1.53","article-title":"Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement","volume":"34","author":"Chin","year":"2019","journal-title":"Endocrinol. Metab."},{"key":"ref_35","first-page":"2136","article-title":"Somatostatin receptors, an expanding gene family: Cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase","volume":"6","author":"Yamada","year":"1992","journal-title":"Mol. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000337659","article-title":"Reassessment of sst3 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-5","volume":"96","author":"Lupp","year":"2012","journal-title":"Neuroendocrinology"},{"key":"ref_37","first-page":"894","article-title":"Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20","volume":"43","author":"Demchyshyn","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1523\/JNEUROSCI.20-10-03785.2000","article-title":"Distribution, targeting, and internalization of the sst4 somatostatin receptor in rat brain","volume":"20","author":"Schreff","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuroscience.2004.04.051","article-title":"The expression and localization of somatostatin receptors in dorsal root ganglion neurons of normal and monoarthritic rats","volume":"127","author":"Schurigt","year":"2004","journal-title":"Neuroscience"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1507\/endocrj.52.605","article-title":"Systemic distribution of somatostatin receptor subtypes in human: An immunohistochemical study","volume":"52","author":"Taniyama","year":"2005","journal-title":"Endocr. J."},{"key":"ref_41","first-page":"417","article-title":"Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28","volume":"45","author":"Panetta","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0888-7543(95)80195-R","article-title":"Localization of human somatostatin receptor 5 gene (SSTR5) to chromosome band 16p13.3 by fluorescence in situ hybridization","volume":"26","author":"Takeda","year":"1995","journal-title":"Genomics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","article-title":"Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin","volume":"142","author":"Stollberg","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.pharmthera.2006.04.010","article-title":"Inhibitory effect of somatostatin on inflammation and nociception","volume":"112","author":"Helyes","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_46","first-page":"615","article-title":"Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease","volume":"20","author":"Casini","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.neuroscience.2008.09.037","article-title":"Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: Behavioral and neurophysiological evidence","volume":"157","author":"Engin","year":"2008","journal-title":"Neuroscience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-009-1605-5","article-title":"Anxiolytic and antidepressant actions of somatostatin: The role of sst2 and sst3 receptors","volume":"206","author":"Engin","year":"2009","journal-title":"Psychopharmacology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.pharmthera.2009.03.010","article-title":"Somatostatin analogues as therapeutics in retinal disease","volume":"122","author":"Vasilaki","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.tem.2009.12.003","article-title":"Pituitary somatostatin receptor signaling","volume":"21","author":"Melmed","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.yhbeh.2015.05.009","article-title":"The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior","volume":"73","author":"Stengel","year":"2015","journal-title":"Horm. Behav."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/npp.2016.281","article-title":"Roles of Hippocampal Somatostatin Receptor Subtypes in Stress Response and Emotionality","volume":"42","author":"Gastambide","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front. Neuroendocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.cellsig.2008.08.015","article-title":"Characterization of voltage operated R-type Ca2+ channels in modulating somatostatin receptor subtype 2- and 3-dependent inhibition of insulin secretion from INS-1 cells","volume":"20","author":"Mergler","year":"2008","journal-title":"Cell. Signal."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1210\/me.2013-1327","article-title":"Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis","volume":"28","author":"Eigler","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10571-017-0471-7","article-title":"Upregulated Expression of SSTR3 is Involved in Neuronal Apoptosis after Intracerebral Hemorrhage in Adult Rats","volume":"37","author":"Yao","year":"2017","journal-title":"Cell Mol. Neurobiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00210-008-0346-z","article-title":"Somatostatin increases rat locomotor activity by activating sst2 and sst4 receptors in the striatum and via glutamatergic involvement","volume":"379","author":"Santis","year":"2009","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/hipo.20680","article-title":"Cooperation between hippocampal somatostatin receptor subtypes 4 and 2: Functional relevance in interactive memory systems","volume":"20","author":"Gastambide","year":"2010","journal-title":"Hippocampus"},{"key":"ref_59","first-page":"1099","article-title":"Intracisternal injection of somatostatin receptor 5-preferring agonists induces a vagal cholinergic stimulation of gastric emptying in rats","volume":"293","author":"Rivier","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Stengel, A., and Tach\u00e9, Y.F. (2017). Activation of Brain Somatostatin Signaling Suppresses CRF Receptor-Mediated Stress Response. Front. Neurosci., 11.","DOI":"10.3389\/fnins.2017.00231"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.2174\/138161209789824795","article-title":"Rhodopsin and the others: A historical perspective on structural studies of G protein-coupled receptors","volume":"15","author":"Costanzi","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bbamem.2006.10.021","article-title":"G protein coupled receptor structure and activation","volume":"1768","author":"Kobilka","year":"2007","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Biomembr."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhang, B., Xue, L., and Wu, Z.B. (2024). Structure and Function of Somatostatin and its Receptors in Endocrinology. Endocr. Rev., bnae022.","DOI":"10.1210\/endrev\/bnae022"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0014-5793(92)81122-3","article-title":"Cloning and expression of a novel mouse somatostatin receptor (SSTR2B)","volume":"311","author":"Vanetti","year":"1992","journal-title":"FEBS Lett."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1210\/jc.2008-2564","article-title":"Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors","volume":"94","author":"Gahete","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0378-1119(95)00059-F","article-title":"Cloning of the gene encoding human somatostatin receptor 2: Sequence analysis of the 5\u2032-flanking promoter region","volume":"159","author":"Greenwood","year":"1995","journal-title":"Gene"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1104\/pp.106.084319","article-title":"The TATA-box sequence in the basal promoter contributes to determining light-dependent gene expression in plants","volume":"142","author":"Kiran","year":"2006","journal-title":"Plant Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Wu, W.-S., and Lai, F.-J. (2015). Functional redundancy of transcription factors explains why most binding targets of a transcription factor are not affected when the transcription factor is knocked out. BMC Syst. Biol., 9.","DOI":"10.1186\/1752-0509-9-S6-S2"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bjp.0702401","article-title":"Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins","volume":"126","author":"Carruthers","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1469-7793.2001.00519.x","article-title":"Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by Gi2-dependent activation of calcineurin and depriming of secretory granules","volume":"535","author":"Gromada","year":"2001","journal-title":"J. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.256.5060.1215","article-title":"G protein activation of a hormone-stimulated phosphatase in human tumor cells","volume":"256","author":"Pan","year":"1992","journal-title":"Science"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1054\/npep.2001.0848","article-title":"Cellular biology of somatostatin receptors","volume":"35","author":"Csaba","year":"2001","journal-title":"Neuropeptides"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mce.2007.12.006","article-title":"Dimerization of G protein-coupled receptors: New avenues for somatostatin receptor signalling, control and functioning","volume":"286","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3220001","article-title":"Regulatory mechanisms that modulate signalling by G-protein-coupled receptors","volume":"322","author":"Grady","year":"1997","journal-title":"Biochem. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12013-018-0850-9","article-title":"Endocytosis of G Protein-Coupled Receptors and Their Ligands: Is There a Role in Metal Trafficking?","volume":"76","author":"Christofides","year":"2018","journal-title":"Cell Biochem. Biophys."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"61s","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin Receptor Antagonists for Imaging and Therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/bs.pmbts.2022.09.004","article-title":"Internalization of somatostatin receptors in brain and periphery","volume":"196","author":"Csaba","year":"2023","journal-title":"Progress Mol. Biol. Transl. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.neuropharm.2004.06.008","article-title":"The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat","volume":"47","author":"Vasilaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1210\/endo.139.3.5977","article-title":"Growth hormone-releasing hormone neurons in the arcuate nucleus express both Sst1 and Sst2 somatostatin receptor genes","volume":"139","author":"Tannenbaum","year":"1998","journal-title":"Endocrinology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/endo.141.3.7349","article-title":"Involvement of the Sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: An in vitro and in vivo antisense study","volume":"141","author":"Lanneau","year":"2000","journal-title":"Endocrinology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.pharmthera.2005.09.003","article-title":"The somatostatin sst1 receptor: An autoreceptor for somatostatin in brain and retina?","volume":"110","author":"Thermos","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1152\/jn.00507.2005","article-title":"Somatostatin presynaptically inhibits both GABA and glutamate release onto rat basal forebrain cholinergic neurons","volume":"96","author":"Momiyama","year":"2006","journal-title":"J. Neurophysiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1471-4892(02)00007-3","article-title":"GDNF and somatostatin in sensory neurones","volume":"3","author":"Malcangio","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1002\/art.30410","article-title":"Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis","volume":"63","author":"Imhof","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00129039-200006000-00007","article-title":"Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas","volume":"8","author":"Stridsberg","year":"2000","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.surg.2004.05.042","article-title":"Double-gene ablation of SSTR1 and SSTR5 results in hyperinsulinemia and improved glucose tolerance in mice","volume":"136","author":"Wang","year":"2004","journal-title":"Surgery"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1210\/en.2008-0883","article-title":"N-type Ca2+-channels in murine pancreatic beta-cells are inhibited by an exclusive coupling with somatostatin receptor subtype 1","volume":"150","author":"Smith","year":"2009","journal-title":"Endocrinology"},{"key":"ref_88","first-page":"402","article-title":"Pituitary cell line GH3 expresses two somatostatin receptor subtypes that inhibit adenylyl cyclase: Functional expression of rat somatostatin receptor subtypes 1 and 2 in human embryonic kidney 293 cells","volume":"45","author":"Garcia","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_89","first-page":"410","article-title":"Rat somatostatin receptor type 1 couples to G proteins and inhibition of cyclic AMP accumulation","volume":"45","author":"Hadcock","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1210\/endo.134.3.7907016","article-title":"The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin-sensitive pathways","volume":"134","author":"Hershberger","year":"1994","journal-title":"Endocrinology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"10357","DOI":"10.1016\/S0021-9258(17)34068-1","article-title":"Subtype-specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2","volume":"269","author":"Hou","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1210\/endo.135.6.7988476","article-title":"Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1\u20135)","volume":"135","author":"Patel","year":"1994","journal-title":"Endocrinology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"18666","DOI":"10.1074\/jbc.272.30.18666","article-title":"Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells","volume":"272","author":"Chen","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00210-001-0509-7","article-title":"Somatostatin (SRIF) modulates distinct signaling pathways in rat pituitary tumor cells; negative coupling of SRIF receptor subtypes 1 and 2 to arachidonic acid release","volume":"365","author":"Cervia","year":"2002","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"28431","DOI":"10.1074\/jbc.M201261200","article-title":"Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration","volume":"277","author":"Buchan","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"735","DOI":"10.15252\/emmm.201404346","article-title":"Pharmacological targeting of the protein synthesis mTOR\/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance","volume":"7","author":"Duluc","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1210\/mend.13.1.0224","article-title":"Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1)","volume":"13","author":"Florio","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"ref_98","first-page":"3882","article-title":"Subcellular distribution of somatostatin sst2A receptors in human tumors of the nervous and neuroendocrine systems: Membranous versus intracellular location","volume":"85","author":"Reubi","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/gut.2004.042002","article-title":"Cellular detection of sst2A receptors in human gastrointestinal tissue","volume":"53","author":"Gugger","year":"2004","journal-title":"Gut"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1210\/en.2013-1683","article-title":"Somatostatin receptors type 2 and 5 expression and localization during human pituitary development","volume":"155","author":"Peineau","year":"2014","journal-title":"Endocrinology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/00001756-199802160-00027","article-title":"Localization of the somatostatin sst2(a) receptor in human cerebral cortex, hippocampus and cerebellum","volume":"9","author":"Schindler","year":"1998","journal-title":"Neuroreport"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1097\/01.jnen.0000186923.50215.50","article-title":"Somatostatin receptor type 2 undergoes plastic changes in the human epileptic dentate gyrus","volume":"64","author":"Csaba","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1744-8069-10-12","article-title":"Somatostatin and its 2A receptor in dorsal root ganglia and dorsal horn of mouse and human: Expression, trafficking and possible role in pain","volume":"10","author":"Shi","year":"2014","journal-title":"Mol. Pain."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000329876","article-title":"Reassessment of sst(5) somatostatin receptor expression in normal and neoplastic human tissues using the novel rabbit monoclonal antibody UMB-4","volume":"94","author":"Lupp","year":"2011","journal-title":"Neuroendocrinology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1055\/s-0032-1314859","article-title":"Differential expression of somatostatin receptor subtype 1\u20135 proteins in numerous human normal tissues","volume":"120","author":"Unger","year":"2012","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"R793","DOI":"10.1152\/ajpregu.00248.2014","article-title":"Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: Role in drinking behavior","volume":"307","author":"Karasawa","year":"2014","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10721","DOI":"10.1016\/S0021-9258(18)82045-2","article-title":"Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2","volume":"268","author":"Law","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"21012","DOI":"10.1074\/jbc.M111.337865","article-title":"PDZ Domain-containing 1 (PDZK1) Protein Regulates Phospholipase C-\u03b23 (PLC-\u03b23)-specific Activation of Somatostatin by Forming a Ternary Complex with PLC-\u03b23 and Somatostatin Receptors*","volume":"287","author":"Kim","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1073\/pnas.91.6.2315","article-title":"Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2","volume":"91","author":"Buscail","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1210\/mend.11.8.9960","article-title":"Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: Coexpression with catalytically inactive SHP-2 blocks responsiveness","volume":"11","author":"Reardon","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"15186","DOI":"10.1074\/jbc.274.21.15186","article-title":"sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1","volume":"274","author":"Benali","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/0008-5472.CAN-05-1189","article-title":"Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression","volume":"66","author":"Theodoropoulou","year":"2006","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/ENEURO.0163-15.2017","article-title":"Shank Proteins Differentially Regulate Synaptic Transmission","volume":"4","author":"Shi","year":"2017","journal-title":"eNeuro"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"40601","DOI":"10.1074\/jbc.M306510200","article-title":"Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: Involvement of Rac and MAP kinase activity","volume":"278","author":"Pola","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1210\/en.2007-1525","article-title":"Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications","volume":"149","author":"Torrisani","year":"2008","journal-title":"Endocrinology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13000-016-0461-y","article-title":"SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males","volume":"11","author":"Shen","year":"2016","journal-title":"Diagn. Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.mce.2014.02.009","article-title":"Carboxyl-terminal multi-site phosphorylation regulates internalization and desensitization of the human sst2 somatostatin receptor","volume":"387","author":"Lehmann","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Trafficking in Vitro","volume":"94","author":"Lesche","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1210\/me.2015-1241","article-title":"Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay","volume":"30","author":"Culler","year":"2016","journal-title":"Mol. Endocrinol."},{"key":"ref_120","first-page":"1688","article-title":"Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3","volume":"10","author":"Sharma","year":"1996","journal-title":"Mol. Endocrinol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"21374","DOI":"10.1074\/jbc.M313522200","article-title":"Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes","volume":"279","author":"Tulipano","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1523\/JNEUROSCI.5295-09.2010","article-title":"Somatostatin signaling in neuronal cilia is critical for object recognition memory","volume":"30","author":"Einstein","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/cns.12259","article-title":"Cortistatin-14 mediates its anticonvulsant effects via sst2 and sst3 but not ghrelin receptors","volume":"20","author":"Aourz","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1152\/jn.00098.2010","article-title":"Modulation of voltage-gated ion channels in rat retinal ganglion cells mediated by somatostatin receptor subtype 4","volume":"104","author":"Farrell","year":"2010","journal-title":"J. Neurophysiol."},{"key":"ref_125","first-page":"265","article-title":"Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery","volume":"94","author":"Fehlmann","year":"2000","journal-title":"J. Physiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/03009734.2015.1035413","article-title":"Somatostatin receptor 1\u20135; expression profiles during rat development","volume":"120","author":"Ludvigsen","year":"2015","journal-title":"Ups. J. Med. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0024-3205(94)00956-2","article-title":"Expression of mRNA for all five human somatostatin receptors (hSSTR1\u20135) in pituitary tumors","volume":"56","author":"Panetta","year":"1995","journal-title":"Life Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_129","first-page":"67","article-title":"Somatostatin receptors in the nucleus accumbens selectively mediate the stimulatory effect of somatostatin on locomotor activity in rats","volume":"265","author":"Raynor","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuropharm.2015.09.021","article-title":"Somatostatin receptor subtype 4 activation is involved in anxiety and depression-like behavior in mouse models","volume":"101","author":"Scheich","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.neuroscience.2017.01.039","article-title":"Higher susceptibility of somatostatin 4 receptor gene-deleted mice to chronic stress-induced behavioral and neuroendocrine alterations","volume":"346","author":"Scheich","year":"2017","journal-title":"Neuroscience"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2014.04.016","article-title":"Somatostatin 4 receptor activation modulates G-protein coupled inward rectifying potassium channels and voltage stimulated calcium signals in dorsal root ganglion neurons","volume":"736","author":"Gorham","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(03)00235-9","article-title":"Somatostatin receptors","volume":"1616","author":"Stidsen","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1210\/en.2008-1785","article-title":"Characterization of intracellular signaling mediated by human somatostatin receptor 5: Role of the DRY motif and the third intracellular loop","volume":"150","author":"Peverelli","year":"2009","journal-title":"Endocrinology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1242\/jcs.116434","article-title":"Specific roles of G(i) protein family members revealed by dissecting SST5 coupling in human pituitary cells","volume":"126","author":"Peverelli","year":"2013","journal-title":"J. Cell Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1517\/13543781003604710","article-title":"The somatostatin receptor subtype 5 in neuroendocrine tumours","volume":"19","author":"Lamberts","year":"2010","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.bjp.0701116","article-title":"Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism","volume":"121","author":"Wilkinson","year":"1997","journal-title":"Br. J. Pharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(97)01430-1","article-title":"Homologous and heterologous desensitisation of somatostatin-induced increases in intracellular Ca2+ and inositol 1,4,5-trisphosphate in CHO-K1 cells expressing human recombinant somatostatin sst5 receptors","volume":"340","author":"Wilkinson","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0306-4522(95)00510-2","article-title":"Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20","volume":"71","author":"Tallent","year":"1996","journal-title":"Neuroscience"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9343","DOI":"10.1073\/pnas.94.17.9343","article-title":"Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype\u2009sst5","volume":"94","author":"Cordelier","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1210\/jcem.86.8.7787","article-title":"Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment","volume":"86","author":"Persani","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1006\/bbrc.2001.6085","article-title":"Somatostatin type V receptor activates c-Jun N-terminal kinases via Galpha(12) family G proteins","volume":"289","author":"Komatsuzaki","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1210\/me.2007-0068","article-title":"The third intracellular loop of the human somatostatin receptor 5 is crucial for arrestin binding and receptor internalization after somatostatin stimulation","volume":"22","author":"Peverelli","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/me.2007-0081","article-title":"Selective regulation of somatostatin receptor subtype signaling: Evidence for constitutive receptor activation","volume":"21","author":"Pichurin","year":"2007","journal-title":"Mol. Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1210\/me.2008-0361","article-title":"Constitutive somatostatin receptor activity determines tonic pituitary cell response","volume":"23","author":"Zhou","year":"2009","journal-title":"Mol. Endocrinol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jsbmb.2013.06.007","article-title":"Somatostatin and its receptors: Functional regulation in the development of mice Sertoli cells","volume":"138","author":"Riaz","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1161\/CIRCRESAHA.112.300695","article-title":"Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation","volume":"112","author":"Morell","year":"2013","journal-title":"Circ. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00259-005-0063-5","article-title":"Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using 68Ga-DOTATOC PET and comparison with 18F-FDG PET","volume":"33","author":"Georgoulias","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13402-011-0025-9","article-title":"Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients","volume":"34","author":"Muscarella","year":"2011","journal-title":"Cell. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Klomp, M.J., Refardt, J., van Koetsveld, P.M., Campana, C., Dalm, S.U., Dogan, F., van Velthuysen, M.F., Feelders, R.A., de Herder, W.W., and Hofland, J. (2023). Epigenetic regulation of SST(2) expression in small intestinal neuroendocrine tumors. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1184436"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3892\/etm.2022.11708","article-title":"Unknown-primary neuroendocrine neoplasms diagnosed by short-acting somatostatin test: Case series in one institution","volume":"25","author":"Chang","year":"2023","journal-title":"Exp. Ther. Med."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Burns, L., Naimi, B., Ronan, M., Xu, H., and Weber, H.C. (2023). Report of a Novel Molecular Profile in Malignant Insulinoma. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041280"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1016\/j.ajpath.2012.01.041","article-title":"Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients","volume":"180","author":"Waser","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/annonc\/mdp334","article-title":"Somatostatin receptor tissue distribution in lung neuroendocrine tumours: A clinicopathologic and immunohistochemical study of 218 \u2018clinically aggressive\u2019 cases","volume":"21","author":"Righi","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"20033","DOI":"10.18632\/oncotarget.7706","article-title":"Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy","volume":"7","author":"Lapa","year":"2016","journal-title":"Oncotarget"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e000980","DOI":"10.1136\/jitc-2020-000980","article-title":"Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung","volume":"8","author":"Kim","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Kim, J.Y., Kim, J., Kim, Y.-i., Yang, D.-H., Yoo, C., Park, I.J., Ryoo, B.-Y., Ryu, J.-S., and Hong, S.-M. (2024). Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-54599-4"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/MPA.0000000000000700","article-title":"Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors","volume":"45","author":"Qian","year":"2016","journal-title":"Pancreas"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1267\/ahc.12006","article-title":"Expression of Somatostatin Receptor (SSTR) Subtypes (SSTR-1, 2A, 3, 4 and 5) in Neuroendocrine Tumors Using Real-time RT-PCR Method and Immunohistochemistry","volume":"45","author":"Mizutani","year":"2012","journal-title":"Acta Histochem. Cytochem."},{"key":"ref_161","first-page":"1865","article-title":"Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A","volume":"6","author":"Schulz","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Agopiantz, M., Carnot, M., Denis, C., Martin, E., and Gauchotte, G. (2023). Hormone Receptor Expression in Meningiomas: A Systematic Review. Cancers, 15.","DOI":"10.3390\/cancers15030980"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Wu, W., Zhou, Y., Wang, Y., Liu, L., Lou, J., Deng, Y., Zhao, P., and Shao, A. (2020). Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01633"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","article-title":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","volume":"86","author":"Leijon","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12020-023-03595-1","article-title":"Somatostatin receptor subtype 2A expression and genetics in 184 paragangliomas: A single center retrospective observational study","volume":"85","author":"Shen","year":"2024","journal-title":"Endocrine"},{"key":"ref_166","unstructured":"Parvizi, N., Alsafi, A., Vergine, M., Ramachandran, R., Martin, N., Palazzo, F., Pinato, D., Sharma, R., Meeran, K., and Dina, R. (2012). Expression of Somatostatin Receptors in Phaeochromocytoma and Paragangliomas. Proceedings of the Endocrine Abstracts, Bioscientifica."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"89958","DOI":"10.18632\/oncotarget.21194","article-title":"Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas","volume":"8","author":"Kaemmerer","year":"2017","journal-title":"Oncotarget"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Hertelendi, M., Belguenani, O., Cherfi, A., Folitar, I., Kollar, G., and Polack, B.D. (2023). Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas\/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review. Biomedicines, 11.","DOI":"10.3390\/biomedicines11041024"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/IJGM.S38594","article-title":"Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment","volume":"6","author":"Adelman","year":"2013","journal-title":"Int. J. Gen. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_173","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J. Endocrinol. Investig."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: Difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr. Pathol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1530\/EJE-13-0134","article-title":"Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas","volume":"169","author":"Mayr","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1507\/endocrj.EJ11-0177","article-title":"Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas","volume":"59","author":"Kato","year":"2012","journal-title":"Endocr. J."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: A large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Montella, L., Ottaviano, M., Morra, R., Pietroluongo, E., De Placido, P., Tortora, M., Sorrentino, C., Facchini, G., De Placido, S., and Giuliano, M. (2022). The Never-Ending History of Octreotide in Thymic Tumors: A Vintage or A Contemporary Drug?. Cancers, 14.","DOI":"10.3390\/cancers14030774"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/jcem.85.4.6547","article-title":"Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro","volume":"85","author":"Ferone","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"rjw188","DOI":"10.1093\/jscr\/rjw188","article-title":"Insulinoma or non-insulinoma pancreatogenous hypoglycemia? A diagnostic dilemma","volume":"2016","author":"Anderson","year":"2016","journal-title":"J. Surg. Case Rep."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/apm.13297","article-title":"Immunohistochemical somatostatin receptor expression in insulinomas","volume":"131","author":"Peltola","year":"2023","journal-title":"Apmis"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Heck","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"369","DOI":"10.33549\/physiolres.932821","article-title":"Dopamine 2 and somatostatin 1\u20135 receptors coexpression in clinically non-functioning pituitary adenomas","volume":"64","author":"Gabalec","year":"2015","journal-title":"Physiol. Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/ERC-14-0472","article-title":"SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary","volume":"22","author":"Lee","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.1210\/jc.2002-021895","article-title":"Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: An in vivo and in vitro study","volume":"88","author":"Bertherat","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12022-007-0014-8","article-title":"Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas\u2014Predominance of receptor subtype 4","volume":"18","author":"Stridsberg","year":"2007","journal-title":"Endocr. Pathol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF02738814","article-title":"Quantitation of somatostatin receptor type 2 in neuroendocrine (Merkel cell) carcinoma of the skin by competitive RT-PCR","volume":"10","author":"Papotti","year":"1999","journal-title":"Endocr. Pathol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000381062","article-title":"Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity","volume":"101","author":"Gardair","year":"2015","journal-title":"Neuroendocrinology"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e20031","DOI":"10.1200\/jco.2015.33.15_suppl.e20031","article-title":"Therapeutic targeting of somatostatin receptors in patients with metastatic Merkel cell carcinoma: A retrospective case series","volume":"33","author":"Anderson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1080\/0284186X.2023.2239481","article-title":"Somatostatin receptor expression in Merkel cell carcinoma: Correlation with clinical data","volume":"62","author":"Fagerstedt","year":"2023","journal-title":"Acta Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1017\/S0022215112002265","article-title":"Neuroendocrine differentiation in head and neck squamous cell carcinoma","volume":"126","author":"Schartinger","year":"2012","journal-title":"J. Laryngol. Otol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s002680020102","article-title":"Distribution and functional significance of somatostatin receptors in malignant melanoma","volume":"25","author":"Lum","year":"2001","journal-title":"World J. Surg."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/5584_2021_626","article-title":"Complex Interaction among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma","volume":"1335","author":"Caruntu","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Zhao, M., Lu, T., Bi, G., Hu, Z., Liang, J., Bian, Y., Feng, M., and Zhan, C. (2023). PLK1 regulating chemoradiotherapy sensitivity of esophageal squamous cell carcinoma through pentose phosphate pathway\/ferroptosis. Biomed. Pharmacother., 168.","DOI":"10.1016\/j.biopha.2023.115711"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Tampa, M., Georgescu, S.R., Mitran, C.I., Mitran, M.I., Matei, C., Scheau, C., Constantin, C., and Neagu, M. (2020). Recent Advances in Signaling Pathways Comprehension as Carcinogenesis Triggers in Basal Cell Carcinoma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9093010"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Mizumoto, A., Ohashi, S., Hirohashi, K., Amanuma, Y., Matsuda, T., and Muto, M. (2017). Molecular Mechanisms of Acetaldehyde-Mediated Carcinogenesis in Squamous Epithelium. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091943"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00428-002-0693-y","article-title":"Somatostatin receptors in nasopharyngeal carcinoma","volume":"441","author":"Loh","year":"2002","journal-title":"Virchows Arch."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"104223","DOI":"10.1016\/j.critrevonc.2023.104223","article-title":"Somatostatin receptor2 (SSTR2) expression, prognostic implications, modifications and potential therapeutic strategies associates with head and neck squamous cell carcinomas","volume":"193","author":"Fan","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Harda, K., Szabo, Z., Szabo, E., Olah, G., Fodor, K., Szasz, C., Mehes, G., Schally, A.V., and Halmos, G. (2018). Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma. Molecules, 23.","DOI":"10.3390\/molecules23071535"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/CMR.0b013e32835b70e9","article-title":"Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma","volume":"23","author":"Valsecchi","year":"2013","journal-title":"Melanoma Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10549-005-2414-0","article-title":"Somatostatin receptors in primary human breast cancer: Quantitative analysis of mRNA for subtypes 1\u20135 and correlation with receptor protein expression and tumor pathology","volume":"92","author":"Kumar","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_202","first-page":"1723","article-title":"Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells","volume":"17","author":"Zou","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/sj.bjc.6600284","article-title":"Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours","volume":"87","author":"Hall","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/gyno.2001.6468","article-title":"Immunohistochemical detection of somatostatin receptors in human ovarian tumors","volume":"84","author":"Schulz","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Priyadarshini, S., Allison, D.B., and Chauhan, A. (2022). Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071394"},{"key":"ref_206","first-page":"3777","article-title":"Expression of somatostatin and its receptor 1\u20135 in endometriotic tissues and cells","volume":"16","author":"Zhao","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41574-019-0245-z","article-title":"Rethinking mechanisms, diagnosis and management of endometriosis","volume":"15","author":"Chapron","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.fertnstert.2016.12.025","article-title":"New developments in the medical treatment of endometriosis","volume":"107","author":"Bedaiwy","year":"2017","journal-title":"Fertil. Steril."},{"key":"ref_209","first-page":"2564","article-title":"High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers","volume":"85","author":"Halmos","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_210","first-page":"2566","article-title":"Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer","volume":"82","author":"Sinisi","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-07-1494","article-title":"Identification of prognostic biomarkers for prostate cancer","volume":"14","author":"Kosari","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/pros.23426","article-title":"Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer","volume":"77","author":"Requena","year":"2017","journal-title":"Prostate"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/bjc.2013.263","article-title":"Somatostatin receptor 1, a novel EBV-associated CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer","volume":"108","author":"Zhao","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"100801","DOI":"10.1016\/j.tranon.2020.100801","article-title":"Evaluation of somatostatin and CXCR4 receptor expression in a large set of prostate cancer samples using tissue microarrays and well-characterized monoclonal antibodies","volume":"13","author":"Werner","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Hennigs, J.K., M\u00fcller, J., Adam, M., Spin, J.M., Riedel, E., Graefen, M., Bokemeyer, C., Sauter, G., Huland, H., and Schlomm, T. (2014). Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100469"},{"key":"ref_216","first-page":"115","article-title":"Somatostatin receptor subtype 2 A (SSTR2A) and HER2 expression in gastric adenocarcinoma","volume":"32","author":"Romiti","year":"2012","journal-title":"Anticancer. Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"726","DOI":"10.4161\/cbt.3.8.962","article-title":"The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells","volume":"3","author":"Hu","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CMAR.S236374","article-title":"Knocking Out SST Gene of BGC823 Gastric Cancer Cell by CRISPR\/Cas9 Enhances Migration, Invasion and Expression of SEMA5A and KLF2","volume":"12","author":"Chen","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_219","first-page":"419","article-title":"Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa","volume":"8","author":"Renzi","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_220","first-page":"205","article-title":"Signal transduction of somatostatin receptors negatively controlling cell proliferation","volume":"94","author":"Ferjoux","year":"2000","journal-title":"J. Physiol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pharmthera.2004.02.002","article-title":"Somatostatin analogues: Multiple roles in cellular proliferation, neoplasia, and angiogenesis","volume":"102","author":"Dasgupta","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-2187-7-5","article-title":"Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosis","volume":"7","author":"War","year":"2012","journal-title":"J. Mol. Signal."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000047824","article-title":"Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53","volume":"12","author":"Teijeiro","year":"2002","journal-title":"Cell Physiol. Biochem."},{"key":"ref_224","first-page":"1380","article-title":"Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells","volume":"25","author":"Liu","year":"2004","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2004.10.014","article-title":"Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238","volume":"42","author":"Lasfer","year":"2005","journal-title":"J. Hepatol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0167-0115(97)00008-6","article-title":"Somatostatin modulates the function of Kupffer cells","volume":"69","author":"Chao","year":"1997","journal-title":"Regul. Pept."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.mce.2007.09.005","article-title":"Future clinical prospects in somatostatin\/cortistatin\/somatostatin receptor field","volume":"286","author":"Dalm","year":"2008","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/gut.2003.036053","article-title":"Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma","volume":"53","author":"Reynaert","year":"2004","journal-title":"Gut"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1478-3231.2005.01057.x","article-title":"Somatostatin inhibits pro-inflammatory cytokine secretion from rat hepatic stellate cells","volume":"25","author":"Lang","year":"2005","journal-title":"Liver Int."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1210\/jc.2009-2487","article-title":"Internalized somatostatin receptor subtype 2 in neuroendocrine tumors of octreotide-treated patients","volume":"95","author":"Reubi","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/0024-3205(76)90263-0","article-title":"Differences in the degradation of hypothalamic releasing factors by rat and human serum","volume":"19","author":"Benuck","year":"1976","journal-title":"Life Sci."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0024-3205(76)90158-2","article-title":"Dissociation of somatostatin effects. Peptides inhibiting the release of growth hormone but not glucagon or insulin in rats","volume":"19","author":"Grant","year":"1976","journal-title":"Life Sci."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1126\/science.867045","article-title":"Somatostatin: Analogs with selected biological activities","volume":"196","author":"Brown","year":"1977","journal-title":"Science"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0006-291X(77)90349-7","article-title":"Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release","volume":"74","author":"Meyers","year":"1977","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/0026-0495(78)90083-5","article-title":"Observations on the growth hormone, insulin, and glucagon release-inhibiting activities of somatostatin analogues","volume":"27","author":"Coy","year":"1978","journal-title":"Metabolism"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/endo-102-2-523","article-title":"Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat","volume":"102","author":"Patel","year":"1978","journal-title":"Endocrinology"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors","volume":"100","author":"Shimon","year":"1997","journal-title":"J. Clin. Investig."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1210\/endo.142.1.7880","article-title":"Novel long-acting somatostatin analog with endocrine selectivity: Potent suppression of growth hormone but not of insulin","volume":"142","author":"Afargan","year":"2001","journal-title":"Endocrinology"},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Gomes-Porras, M., C\u00e1rdenas-Salas, J., and \u00c1lvarez-Escol\u00e1, C. (2020). Somatostatin Analogs in Clinical Practice: A Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051682"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4155\/tde-2017-0064","article-title":"Progress in the Formulation and Delivery of Somatostatin Analogs for Acromegaly","volume":"8","author":"Fattah","year":"2017","journal-title":"Ther. Deliv."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward oral delivery of biopharmaceuticals: An assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201\u2013995: A very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1046\/j.1526-4610.2003.03139.x","article-title":"Acromegaly: A Unique Human Headache Model","volume":"43","author":"Levy","year":"2003","journal-title":"Headache J. Head. Face Pain."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","article-title":"Pasireotide-a novel somatostatin receptor ligand after 20 years of use","volume":"23","author":"Bolanowski","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00002030-199207000-00015","article-title":"Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases","volume":"6","author":"Girard","year":"1992","journal-title":"AIDS"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1476-5381.1993.tb13703.x","article-title":"Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria","volume":"109","author":"Dimech","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"ref_247","first-page":"7","article-title":"Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism","volume":"269","author":"Betoin","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(95)00168-K","article-title":"In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin","volume":"279","author":"Advenier","year":"1995","journal-title":"Eur. J. Pharmacol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2125.1999.00878.x","article-title":"The effects of vapreotide, a somatostatin analogue, on gastric acidity, gallbladder emptying and hormone release after 1 week of continuous subcutaneous infusion in normal subjects","volume":"47","author":"Ritz","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM200101043440104","article-title":"Early administration of vapreotide for variceal bleeding in patients with cirrhosis","volume":"344","author":"Masliah","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0016-5107(02)99991-8","article-title":"Early administration of vapreotide for variceal bleeding in patients with cirrhosis","volume":"55","author":"Eloubeidi","year":"2002","journal-title":"Gastrointest. Endosc."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1023\/A:1021754919519","article-title":"Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis","volume":"48","author":"Veal","year":"2003","journal-title":"Dig. Dis. Sci."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/17474124.2.2.185","article-title":"Vapreotide acetate for the treatment of esophageal variceal bleeding","volume":"2","year":"2008","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1517\/14656560903207019","article-title":"Vapreotide: A somatostatin analog for the treatment of acute variceal bleeding","volume":"10","author":"Fortune","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000350468","article-title":"Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor","volume":"20","author":"Spitsin","year":"2013","journal-title":"Neuroimmunomodulation"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0168-8278(02)00170-8","article-title":"Vapreotide in variceal bleeding","volume":"37","author":"Patch","year":"2002","journal-title":"J. Hepatol."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jsps.2018.07.004","article-title":"Targeting of somatostatin receptors expressed in blood cells using quantum dots coated with vapreotide","volume":"26","author":"Abdellatif","year":"2018","journal-title":"Saudi Pharm. J."},{"key":"ref_258","first-page":"445","article-title":"Vapreotide labeled with Tc-99m for imaging tumors","volume":"9","author":"Thakur","year":"1996","journal-title":"Int. J. Oncol."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjc.6690226","article-title":"Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer","volume":"79","author":"Dobbs","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1016\/j.biomaterials.2014.03.012","article-title":"Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles","volume":"35","author":"Feng","year":"2014","journal-title":"Biomaterials"},{"key":"ref_261","doi-asserted-by":"crossref","unstructured":"Dasgupta, P., G\u0171nther, T., and Schulz, S. (2021). Pharmacological Characterization of Veldoreotide as a Somatostatin Receptor 4 Agonist. Life, 11.","DOI":"10.3390\/life11101075"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/0024-3205(84)90009-2","article-title":"A super active cyclic hexapeptide analog of somatostatin","volume":"34","author":"Veber","year":"1984","journal-title":"Life Sci."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2165\/00003495-198938050-00002","article-title":"Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion","volume":"38","author":"Battershill","year":"1989","journal-title":"Drugs"},{"key":"ref_264","unstructured":"Novartis Pharmaceuticals Corporation (2002). Sandostatin. Octreotide Acetate Injection, Novartis Pharmaceuticals Corporation."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.metabol.2005.04.014","article-title":"Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel","volume":"54","author":"Cendros","year":"2005","journal-title":"Metabolism"},{"key":"ref_266","unstructured":"Center for Drug Evaluation and Research (2020). FDA Approved Products: Mycapssa (Octreotide) Oral Delayed-Release Capsules."},{"key":"ref_267","unstructured":"Center for Drug Evaluation and Research (2012). FDA Approved Drug Products: Signifor (Pasireotide Diaspartate) Injection, for Subcutaneous Use."},{"key":"ref_268","unstructured":"Center for Drug Evaluation and Research (2019). FDA Approved Drug Products: Somatuline Depot (Lanreotide) for Subcutaneous Injection."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/TCRM.S183360","article-title":"Octreotide-Resistant Acromegaly: Challenges and Solutions","volume":"16","author":"Corica","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The Future of Somatostatin Receptor Ligands in Acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/dme.13823","article-title":"Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia","volume":"36","author":"Banerjee","year":"2019","journal-title":"Diabet. Med."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/0284186X.2017.1342864","article-title":"Somatostatin receptor expression in lymphomas: A source of false diagnosis of neuroendocrine tumor at 68Ga-DOTANOC PET\/CT imaging","volume":"57","author":"Ruuska","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_274","doi-asserted-by":"crossref","unstructured":"Guida, M., D\u2019Al\u00f2, A., Mangia, A., Di Pinto, F., Sonnessa, M., Albano, A., Sciacovelli, A., Asabella, A.N., and Fucci, L. (2020). Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog alone or in Association with Checkpoint Inhibitors Immunotherapy. A Case Report. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01073"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjd.19150","article-title":"High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma","volume":"184","author":"Akaike","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_276","unstructured":"Feingold, K.R., Anawalt, B., Blackman, M.R., Boyce, A., Chrousos, G., Corpas, E., de Herder, W.W., Dhatariya, K., Dungan, K., and Hofland, J. (2000). Insulinoma. Endotext, MDText.com, Inc."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_278","first-page":"903","article-title":"Treatment of hepatocellular carcinoma with long acting somatostatin analogues","volume":"9","author":"Samonakis","year":"2002","journal-title":"Oncol. Rep."},{"key":"ref_279","doi-asserted-by":"crossref","unstructured":"Puig-Domingo, M., Bernab\u00e9u, I., Pic\u00f3, A., Biagetti, B., Gil, J., Alvarez-Escol\u00e1, C., Jord\u00e0, M., Marques-Pamies, M., Soldevila, B., and G\u00e1lvez, M.-A. (2021). Pasireotide in the Personalized Treatment of Acromegaly. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.648411"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s11102-016-0734-1","article-title":"Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly","volume":"19","author":"Silverstein","year":"2016","journal-title":"Pituitary"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: Results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_282","first-page":"145","article-title":"Neuroendocrine tumors. Biotherapy","volume":"21","author":"Wiedenmann","year":"2007","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5732\/cjc.012.10295","article-title":"Pancreatic neuroendocrine tumors: Biology, diagnosis, and treatment","volume":"32","author":"Ro","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s40265-015-0397-7","article-title":"The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors","volume":"75","author":"Cives","year":"2015","journal-title":"Drugs"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0950-351X(96)80362-4","article-title":"Somatostatin receptors and disease: Role of receptor subtypes","volume":"10","author":"Hofland","year":"1996","journal-title":"Bailli\u00e8re\u2019s Clin. Endocrinol. Metab."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0885-3924(94)90144-9","article-title":"Subcutaneous octreotide in the treatment of pain in advanced cancer patients","volume":"9","author":"Saita","year":"1994","journal-title":"J. Pain Symptom Manag."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpainsymman.2010.05.002","article-title":"Octreotide","volume":"40","author":"Murphy","year":"2010","journal-title":"J. Pain Symptom Manag."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/EJE-19-0074","article-title":"ANNIVERSARY REVIEW: Octreotide, 40 years later","volume":"181","author":"Lamberts","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jcem.82.9.4257","article-title":"Acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2265.2009.03706.x","article-title":"Effects of octreotide exposure during pregnancy in acromegaly","volume":"72","author":"Maffei","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.anclin.2017.01.021","article-title":"Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks","volume":"35","author":"Borna","year":"2017","journal-title":"Anesthesiol. Clin."},{"key":"ref_292","first-page":"752","article-title":"Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses","volume":"76","author":"Boyle","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1345\/aph.1C076","article-title":"Octreotide for sulfonylurea-induced hypoglycemia following overdose","volume":"36","author":"Carr","year":"2002","journal-title":"Ann. Pharmacother."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/emj.2007.051326","article-title":"Use of octreotide acetate to prevent rebound hypoglycaemia in sulfonylurea overdose","volume":"24","author":"Hassan","year":"2007","journal-title":"Emerg. Med. J."},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3109\/15563650.2012.734626","article-title":"Octreotide for the treatment of sulfonylurea poisoning","volume":"50","author":"Glatstein","year":"2012","journal-title":"Clin. Toxicol."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2337\/dc14-0565","article-title":"Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it\u2019s time to move on!","volume":"38","author":"Genuth","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"840","DOI":"10.5114\/aoms.2015.53304","article-title":"Sulfonylureas and their use in clinical practice","volume":"11","author":"Sola","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2174\/1573399816666200206112318","article-title":"Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications","volume":"16","author":"Vaughan","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of Type 2 Diabetes\u2014Global Burden of Disease and Forecasted Trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_300","doi-asserted-by":"crossref","unstructured":"Neagu, M., Constantin, C., Surcel, M., Munteanu, A., Scheau, C., Savulescu-Fiedler, I., and Caruntu, C. (2023). Diabetic neuropathy: A NRF2 disease?. J. Diabetes, 1\u201317.","DOI":"10.1111\/1753-0407.13524"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jemermed.2012.11.099","article-title":"Octreotide for the treatment of hypoglycemia after insulin glargine overdose","volume":"45","author":"Groth","year":"2013","journal-title":"J. Emerg. Med."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.mehy.2013.05.036","article-title":"Octreotide may attenuate absorption and ameliorate toxicity following enteric drug overdose","volume":"81","author":"Harvey","year":"2013","journal-title":"Med. Hypotheses"},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/0140-6736(91)92346-4","article-title":"Biliary colic on abrupt withdrawal of octreotide","volume":"338","author":"James","year":"1991","journal-title":"Lancet"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0002-9343(91)90675-N","article-title":"Acute pancreatitis following octreotide withdrawal","volume":"90","author":"Sadoul","year":"1991","journal-title":"Am. J. Med."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0140-6736(92)91702-A","article-title":"Side-effects of octreotide withdrawal","volume":"339","author":"Sadoul","year":"1992","journal-title":"Lancet"},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S1567-5769(01)00098-4","article-title":"Modulatory effects of octreotide on anti-CD3 and dexamethasone-induced apoptosis of murine thymocytes","volume":"1","author":"Trobonjaca","year":"2001","journal-title":"Int. Immunopharmacol."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.npep.2007.06.003","article-title":"Changes in thymus size, cellularity and relation between thymocyte subpopulations in young adult rats induced by somatostatin-14","volume":"41","author":"Rakin","year":"2007","journal-title":"Neuropeptides"},{"key":"ref_308","first-page":"103","article-title":"Activation of rat thymocytes selectively upregulates the expression of somatostatin receptor subtype-1","volume":"38","author":"Sedqi","year":"1996","journal-title":"Biochem. Mol. Biol. Int."},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/1521-4141(200206)32:6<1550::AID-IMMU1550>3.0.CO;2-W","article-title":"Somatostatin is expressed in the murine thymus and enhances thymocyte development","volume":"32","author":"Solomou","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM199701233360405","article-title":"Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone","volume":"336","author":"Palmieri","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1080\/02841860701203578","article-title":"Resolution of thymoma-related pure red cell aplasia after octreotide treatment","volume":"46","author":"Zaucha","year":"2007","journal-title":"Acta Oncol."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/MPH.0b013e318159a535","article-title":"Advanced pediatric inoperable thymus carcinoma (type C thymoma): Case report on a novel therapeutic approach","volume":"29","author":"Kertesz","year":"2007","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.48.1922","article-title":"Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone","volume":"48","author":"Ito","year":"2009","journal-title":"Intern. Med."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1259\/bjr\/16436465","article-title":"The role of somatostatin analogues in the treatment of advanced malignant thymomas: Case report and review of the literature","volume":"84","author":"Pettit","year":"2011","journal-title":"Br. J. Radiol."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"e13286","DOI":"10.1097\/MD.0000000000013286","article-title":"Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report","volume":"97","author":"Mei","year":"2018","journal-title":"Medicine"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.rpor.2020.08.012","article-title":"Octreotide in the treatment of malignant thymoma\u2014Case report","volume":"25","author":"Sorejs","year":"2020","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1200\/JCO.2004.02.047","article-title":"Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group Phase II Trial","volume":"22","author":"Loehrer","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_318","doi-asserted-by":"crossref","unstructured":"Kirzinger, L., Boy, S., Marienhagen, J., Schuierer, G., Neu, R., Ried, M., Hofmann, H.S., Wiebe, K., Str\u00f6bel, P., and May, C. (2016). Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168215"},{"key":"ref_319","first-page":"S2066","article-title":"P1.17-015 Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience","volume":"12","author":"Ottaviano","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1210\/jc.2003-031575","article-title":"Non-islet origin of pancreatic islet cell tumors","volume":"89","author":"Vortmeyer","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_321","first-page":"749","article-title":"An update on gastroenteropancreatic neuroendocrine tumors","volume":"28","author":"Cives","year":"2014","journal-title":"Oncology"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tum ours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","article-title":"Expression of somatostatin receptor types 1\u20135 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis","volume":"440","author":"Papotti","year":"2002","journal-title":"Virchows Arch."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40618-023-02170-9","article-title":"Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: A 20-year-old story","volume":"47","author":"Faggiano","year":"2024","journal-title":"J. Endocrinol. Investig."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"647","DOI":"10.15403\/jgld-2866","article-title":"MicroRNAs and Treatment with Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Challenges in Personalized Medicine","volume":"29","author":"Curt","year":"2020","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11154-023-09858-6","article-title":"Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors","volume":"25","author":"Ruggeri","year":"2024","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"Ducreux","year":"2000","journal-title":"Cancer"},{"key":"ref_329","first-page":"e7186","article-title":"Carcinoid Syndrome: A Review","volume":"12","author":"Gade","year":"2020","journal-title":"Cureus"},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"e490s","DOI":"10.6061\/clinics\/2018\/e490s","article-title":"Carcinoid syndrome: Update on the pathophysiology and treatment","volume":"73","author":"Glasberg","year":"2018","journal-title":"Clinics"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000461583","article-title":"ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors","volume":"105","author":"Kaltsas","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.surg.2015.05.036","article-title":"Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis","volume":"159","author":"Condron","year":"2016","journal-title":"Surgery"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2967\/jnumed.123.265706","article-title":"Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients","volume":"65","author":"Strosberg","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2013-0369","article-title":"Zollinger-Ellison syndrome: Classical considerations and current controversies","volume":"19","author":"Epelboym","year":"2014","journal-title":"Oncologist"},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004280100494","article-title":"Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy","volume":"439","author":"Papotti","year":"2001","journal-title":"Virchows Arch."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","article-title":"The role of somatostatin and its analogs in the diagnosis and treatment of tumors","volume":"12","author":"Lamberts","year":"1991","journal-title":"Endocr. Rev."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol."},{"key":"ref_340","first-page":"76s","article-title":"Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: Implications for follow-up after therapy","volume":"46","author":"Krenning","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_341","first-page":"3455","article-title":"Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization","volume":"54","author":"Reubi","year":"1994","journal-title":"Cancer Res."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jcem.83.10.5314","article-title":"Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets","volume":"83","author":"Reubi","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_343","first-page":"2375","article-title":"Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies","volume":"58","author":"Janson","year":"1998","journal-title":"Cancer Res."},{"key":"ref_344","first-page":"3483","article-title":"Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors","volume":"5","author":"Kimura","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_345","first-page":"2942","article-title":"Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: Facts and artifacts","volume":"84","author":"Reubi","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00019606-200003000-00008","article-title":"Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung","volume":"9","author":"Papotti","year":"2000","journal-title":"Diagn. Mol. Pathol."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1097\/01.pas.0000174013.14569.90","article-title":"Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: Lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography","volume":"29","author":"Eltschinger","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_348","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/modpathol.3800954","article-title":"Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy","volume":"20","author":"Volante","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.prp.2012.05.014","article-title":"Differential expression of somatostatin receptors 1\u20135 in neuroendocrine carcinoma of the lung","volume":"208","author":"Tsuta","year":"2012","journal-title":"Pathol. Res. Pract."},{"key":"ref_350","doi-asserted-by":"crossref","unstructured":"Raso, M.G., Bota-Rabassedas, N., and Wistuba, I.I. (2021). Pathology and Classification of SCLC. Cancers, 13.","DOI":"10.3390\/cancers13040820"},{"key":"ref_351","doi-asserted-by":"crossref","unstructured":"\u015een, F., Sheikh, G.T., von Hinten, J., Schindele, A., Kircher, M., Dierks, A., Pfob, C.H., Serfling, S.E., Buck, A.K., and Pelzer, T. (2023). In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target. Cancers, 15.","DOI":"10.3390\/cancers15143595"},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-319-24932-2_7","article-title":"Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer","volume":"890","author":"Kruglyak","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_353","doi-asserted-by":"crossref","unstructured":"Cainap, C., Balacescu, O., Cainap, S.S., and Pop, L.A. (2021). Next Generation Sequencing Technology in Lung Cancer Diagnosis. Biology, 10.","DOI":"10.3390\/biology10090864"},{"key":"ref_354","first-page":"1453","article-title":"Next Generation Sequencing in Clinical Oncology: Applications, Challenges and Promises: A Review Article","volume":"47","author":"Houri","year":"2018","journal-title":"Iran. J. Public Health"},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.med.47.1.57","article-title":"Endocrine tumors of the gastrointestinal tract","volume":"47","author":"Perry","year":"1996","journal-title":"Annu. Rev. Med."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2967\/jnumed.109.068957","article-title":"Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors","volume":"51","author":"Krenning","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hoc.2015.09.009","article-title":"Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors","volume":"30","author":"Kwekkeboom","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11912-017-0567-8","article-title":"Radionuclide Therapy for Neuroendocrine Tumors","volume":"19","author":"Cives","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s00259-018-4158-1","article-title":"Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours","volume":"46","author":"Brabander","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"630","DOI":"10.21614\/chirurgia.114.5.630","article-title":"Pancreatic Neuroendocrine Tumors\u2014Case Series and Literature Review","volume":"114","author":"Mihalache","year":"2019","journal-title":"Chirurgia"},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1572-0241.1998.066_c.x","article-title":"Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors","volume":"93","author":"Krausz","year":"1998","journal-title":"Am. J. Gastroenterol."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/qjmed\/91.4.295","article-title":"Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): A comparative study with CT and MR imaging","volume":"91","author":"Shi","year":"1998","journal-title":"Qjm"},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","article-title":"68Ga-DOTA-NOC PET\/CT imaging of neuroendocrine tumors: Comparison with 111In-DTPA-octreotide (OctreoScan\u00ae)","volume":"13","author":"Krausz","year":"2011","journal-title":"Mol. Imaging Biol."},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1754-9485.2011.02327.x","article-title":"High management impact of Ga-68 DOTATATE (GaTate) PET\/CT for imaging neuroendocrine and other somatostatin expressing tumours","volume":"56","author":"Hofman","year":"2012","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","article-title":"Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors","volume":"54","author":"Wild","year":"2013","journal-title":"J. Nucl. Med."},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/RLU.0000000000000257","article-title":"Predictive value of 68Ga-DOTANOC PET\/CT in patients with suspicion of neuroendocrine tumors: Is its routine use justified?","volume":"39","author":"Sharma","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00261-014-0219-5","article-title":"Evaluation of 68Ga-DOTANOC PET\/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors","volume":"40","author":"Sharma","year":"2015","journal-title":"Abdom. Imaging"},{"key":"ref_369","first-page":"69","article-title":"Somatostatin receptor based PET\/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma","volume":"60","author":"Sharma","year":"2016","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_370","doi-asserted-by":"crossref","unstructured":"Eschbach, R.S., Hofmann, M., Sp\u00e4th, L., Sheikh, G.T., Delker, A., Lindner, S., Jurkschat, K., W\u00e4ngler, C., W\u00e4ngler, B., and Schirrmacher, R. (2023). Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.992316"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/RLU.0000000000004776","article-title":"The Influence of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors","volume":"48","author":"Chahid","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.3390\/cimb44110373","article-title":"Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review","volume":"44","author":"Poletto","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.rcl.2008.03.005","article-title":"Overview of lymphoma diagnosis and management","volume":"46","author":"Matasar","year":"2008","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_374","doi-asserted-by":"crossref","unstructured":"Zamfir, M.-A., Moraru, L., Dobrea, C., Scheau, A.-E., Iacob, S., Moldovan, C., Scheau, C., Caruntu, C., and Caruntu, A. (2022). Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina, 58.","DOI":"10.3390\/medicina58070874"},{"key":"ref_375","first-page":"8","article-title":"Somatostatin receptors in malignant lymphomas: Targets for radiotherapy?","volume":"45","author":"Dalm","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/j.semnuclmed.2005.03.001","article-title":"Initial staging of lymphoma with octreotide and other receptor imaging agents","volume":"35","author":"Ferone","year":"2005","journal-title":"Semin. Nucl. Med."},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1054\/bjoc.2001.2070","article-title":"Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type","volume":"85","author":"Raderer","year":"2001","journal-title":"Br. J. Cancer"},{"key":"ref_378","first-page":"222","article-title":"Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin\u2019s lymphomas","volume":"42","author":"Lugtenburg","year":"2001","journal-title":"J. Nucl. Med."},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archderm.1972.01620040075020","article-title":"Trabecular carcinoma of the skin","volume":"105","author":"Toker","year":"1972","journal-title":"Arch. Dermatol."},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","article-title":"Merkel cell carcinoma","volume":"3","author":"Becker","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_381","doi-asserted-by":"crossref","unstructured":"Apraiz, A., Benedicto, A., Marquez, J., Ag\u00fcera-Lorente, A., Asumendi, A., Olaso, E., and Arteta, B. (2020). Innate Lymphoid Cells in the Malignant Melanoma Microenvironment. Cancers, 12.","DOI":"10.3390\/cancers12113177"},{"key":"ref_382","doi-asserted-by":"crossref","unstructured":"Reynaert, H., and Colle, I. (2019). Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194811"},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jhep.2012.09.026","article-title":"Marginal survival benefit in the treatment of early hepatocellular carcinoma","volume":"58","author":"Midorikawa","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/jjco\/hyw133","article-title":"Early hepatocellular carcinoma as a signaling lesion for subsequent malignancy","volume":"46","author":"Midorikawa","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.surg.2016.04.019","article-title":"Natural history of nonenhancing lesions incidentally detected during the diagnosis of hepatocellular carcinoma","volume":"160","author":"Ebisawa","year":"2016","journal-title":"Surgery"},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.surg.2017.12.022","article-title":"Liver resection for recurrent hepatocellular carcinoma to improve survivability: A proposal of indication criteria","volume":"163","author":"Yagi","year":"2018","journal-title":"Surgery"},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"5965","DOI":"10.3390\/cimb46060356","article-title":"MASLD-Related HCC: A Comprehensive Review of the Trends, Pathophysiology, Tumor Microenvironment, Surveillance, and Treatment Options","volume":"46","author":"Shi","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.3390\/cimb46070376","article-title":"MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development","volume":"46","author":"Khaznadar","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/apt.15812","article-title":"Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy","volume":"52","author":"Wiese","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_390","doi-asserted-by":"crossref","unstructured":"Choe, J.W., Hyun, J.J., Kim, B., and Han, K.D. (2021). Influence of Metabolic Syndrome on Cancer Risk in HBV Carriers: A Nationwide Population Based Study Using the National Health Insurance Service Database. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112401"},{"key":"ref_391","doi-asserted-by":"crossref","unstructured":"Jeon, H., Kim, J.H., Lee, S.S., Kim, H.J., Cha, R.R., Cho, H.C., Lee, J.M., Ha, C.Y., Kim, H.J., and Kim, T.H. (2021). Impact of acute kidney injury on survival in patients with chronic hepatitis C: A retrospective cohort study. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-05991-2"},{"key":"ref_392","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: Incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/00365520510024043","article-title":"Octreotide in the treatment of refractory ascites of cirrhosis","volume":"41","author":"Kalambokis","year":"2006","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s10620-008-0566-6","article-title":"The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis","volume":"54","author":"Zhou","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"ref_395","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gut.42.3.442","article-title":"Treatment of hepatocellular carcinoma with octreotide: A randomised controlled study","volume":"42","author":"Kouroumalis","year":"1998","journal-title":"Gut"},{"key":"ref_396","first-page":"766","article-title":"Efficacy of octreotide in advanced hepatocellular carcinoma: A clinical trial","volume":"7","author":"Wu","year":"2001","journal-title":"Chin. J. Hepatobiliary Surg."},{"key":"ref_397","first-page":"211","article-title":"Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: A randomized controlled trial","volume":"2","author":"Pan","year":"2003","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_398","first-page":"302","article-title":"Effects of octreotide in elderly patients with advanced primary hepatic cancer","volume":"4","author":"Yang","year":"2003","journal-title":"J. Clin. Med. Pract."},{"key":"ref_399","first-page":"69","article-title":"Octreotide in the treatment of inoperable hepatocellular carcinoma","volume":"17","author":"Patsanas","year":"2004","journal-title":"Ann. Gastroenterol."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00432-006-0118-4","article-title":"Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma","volume":"132","author":"Treiber","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.3748\/wjg.v13.i23.3164","article-title":"Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial","volume":"13","author":"Dimitroulopoulos","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_402","first-page":"19","article-title":"Clinical study of octreotide for advanced hepatocellular carcinoma","volume":"18","author":"Ou","year":"2007","journal-title":"Hainan Med. J."},{"key":"ref_403","first-page":"385","article-title":"Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: A single center experience","volume":"20","author":"Montella","year":"2008","journal-title":"Oncol. Rep."},{"key":"ref_404","first-page":"45","article-title":"A Phase II Study of Long-Acting Octreotide in Patients with Advanced Hepatocellular Carcinoma and CLIP Score of 3 or Higher","volume":"3","author":"Shah","year":"2009","journal-title":"Gastrointest. Cancer Res."},{"key":"ref_405","first-page":"52","article-title":"The clinical observation of octreotide in the treatment of 45 patients with advanced primary liver carcinoma","volume":"23","author":"Zhang","year":"2010","journal-title":"J. Basic Clin. Oncol."},{"key":"ref_406","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00280-009-1226-z","article-title":"Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: Multicenter phase II So.LAR. study","volume":"66","author":"Prete","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1038\/cddis.2011.34","article-title":"Oxidative stress and ERK1\/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR","volume":"2","author":"Caraglia","year":"2011","journal-title":"Cell Death Dis."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3892\/ol.2013.1435","article-title":"Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment","volume":"6","author":"Liu","year":"2013","journal-title":"Oncol. Lett."},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"48303","DOI":"10.18632\/oncotarget.15684","article-title":"Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: A randomized pilot study","volume":"8","author":"Tong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_410","first-page":"1197","article-title":"Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo","volume":"16","author":"Raderer","year":"2000","journal-title":"Int. J. Oncol."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/jhep.2002.35071","article-title":"A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma","volume":"36","author":"Yuen","year":"2002","journal-title":"Hepatology"},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-2002-32129","article-title":"Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide","volume":"40","author":"Rabe","year":"2002","journal-title":"Z. Gastroenterol."},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1440-1746.2005.03959.x","article-title":"Hepatocellular carcinoma and octreotide: Treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage","volume":"20","author":"Plentz","year":"2005","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bjc.6603325","article-title":"Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide","volume":"95","author":"Cebon","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.bjc.6603901","article-title":"Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: A randomised multicentre phase III study","volume":"97","author":"Verset","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.21468","article-title":"Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study","volume":"45","author":"Becker","year":"2007","journal-title":"Hepatology"},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.ejca.2009.02.018","article-title":"Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study","volume":"45","author":"Barbare","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_418","unstructured":"(2006). Lanreotide, Drugs and Lactation Database (LactMed\u00ae)."},{"key":"ref_419","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40487-022-00208-1","article-title":"Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study","volume":"10","author":"Paulson","year":"2022","journal-title":"Oncol. Ther."},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2022.07.033","article-title":"Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial\u2014Prodige 31 REMINET: An FFCD study","volume":"175","author":"Lepage","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_421","first-page":"265","article-title":"Neuroendocrine tumor chromogranin A response following synthetic somatostatin analog (lanreotide): Early observations from an isolated duodenal neoplasm","volume":"44","author":"Sills","year":"2023","journal-title":"Neuro Endocrinol. Lett."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/ejendo\/lvad094","article-title":"OPERA: Perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel","volume":"189","author":"Hautefeuille","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s12325-022-02360-6","article-title":"PRESTO 2: An International Survey to Evaluate Patients\u2019 Injection Experiences with the Latest Devices\/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly","volume":"40","author":"Kunz","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"e13281","DOI":"10.1111\/jne.13281","article-title":"Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey","volume":"35","author":"Hernando","year":"2023","journal-title":"J. Neuroendocrinol."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"e1533","DOI":"10.1200\/OP.22.00055","article-title":"A Randomized Trial Evaluating Patient Experience and Preference between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors","volume":"18","author":"Raj","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1093\/oncolo\/oyad325","article-title":"Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study","volume":"29","author":"Pavel","year":"2024","journal-title":"Oncologist"},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/14740338.2024.2365823","article-title":"An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors","volume":"23","author":"Sood","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/neup.12959","article-title":"Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report","volume":"44","author":"Shiraishi","year":"2024","journal-title":"Neuropathology"},{"key":"ref_429","unstructured":"(2006). Pasireotide, Drugs and Lactation Database (LactMed\u00ae)."},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr. Rev."},{"key":"ref_432","first-page":"134","article-title":"111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: In vivo evidence of the possible down-regulation of somatostatin receptors","volume":"39","author":"Ronga","year":"1995","journal-title":"Q. J. Nucl. Med."},{"key":"ref_433","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jss.2004.03.006","article-title":"Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR","volume":"119","author":"Li","year":"2004","journal-title":"J. Surg. Res."},{"key":"ref_434","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa1313688","article-title":"Pasireotide for postoperative pancreatic fistula","volume":"370","author":"Allen","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1507\/endocrj.EJ22-0560","article-title":"Complete and sustained remission of hypercortisolism with pasireotide treatment of an adrenocorticotropic hormone (ACTH)-secreting thoracic neuroendocrine tumor: An n-of-1 trial","volume":"70","author":"Efstathiadou","year":"2023","journal-title":"Endocr. J."},{"key":"ref_437","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10637-015-0209-7","article-title":"Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma","volume":"33","author":"Sanoff","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_438","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/JHC.S153672","article-title":"Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma","volume":"5","author":"Feun","year":"2018","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.6604315","article-title":"Imaging dopamine receptors in the human brain by positron tomography","volume":"221","author":"Wagner","year":"1983","journal-title":"Science"},{"key":"ref_440","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s12020-024-03779-3","article-title":"Somatostatin receptor imaging of thyroid tissue and differentiated thyroid cancer using gallium-68-labeled radiotracers\u2014A review of clinical studies","volume":"85","author":"Pishdad","year":"2024","journal-title":"Endocrine"},{"key":"ref_441","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cpet.2024.03.008","article-title":"Neuroendocrine Tumors: Diagnostics","volume":"19","author":"Sakellis","year":"2024","journal-title":"PET Clin."},{"key":"ref_442","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/PPO.0000000000000723","article-title":"Theranostics in Neuroendocrine Tumors","volume":"30","author":"Mallak","year":"2024","journal-title":"Cancer J."},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.120.251512","article-title":"Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects","volume":"62","author":"Park","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_444","first-page":"709","article-title":"Identification and characterization of novel somatostatin antagonists","volume":"50","author":"Bass","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_446","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2967\/jnumed.111.088922","article-title":"First clinical evidence that imaging with somatostatin receptor antagonists is feasible","volume":"52","author":"Wild","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2967\/jnumed.112.102764","article-title":"Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications","volume":"53","author":"Fani","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_448","doi-asserted-by":"crossref","unstructured":"Modarai, S.R., Opdenaker, L.M., Viswanathan, V., Fields, J.Z., and Boman, B.M. (2016). Somatostatin signaling via SSTR1 contributes to the quiescence of colon cancer stem cells. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2969-7"},{"key":"ref_449","doi-asserted-by":"crossref","unstructured":"Kasprzak, A., and Geltz, A. (2024). The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030578"},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"7033","DOI":"10.1016\/S0021-9258(18)83536-0","article-title":"Characterization of 17-beta-estradiol-dependent and -independent somatostatin receptor subtypes in rat anterior pituitary","volume":"264","author":"Kimura","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_451","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000097484","article-title":"Hemorrhage results in hepatic insulin-sensitizing substance-dependent insulin resistance mediated by somatostatin in rats","volume":"84","author":"Seredycz","year":"2006","journal-title":"Neuroendocrinology"},{"key":"ref_452","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.neuroscience.2009.01.053","article-title":"Somatostatin receptors in the nucleus accumbens modulate dopamine-dependent but not acetylcholine-dependent turning behaviour of rats","volume":"159","author":"Ikeda","year":"2009","journal-title":"Neuroscience"},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00213-012-2961-0","article-title":"Somatostatin antagonist induces catalepsy in the aged rat","volume":"227","author":"Ionov","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.brainres.2017.04.017","article-title":"Intrahippocampal injection of Cortistatin-14 impairs recognition memory consolidation in mice through activation of sst2, ghrelin and GABAA\/B receptors","volume":"1666","author":"Jiang","year":"2017","journal-title":"Brain Res."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neulet.2018.07.012","article-title":"Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation","volume":"684","author":"Ionov","year":"2018","journal-title":"Neurosci. Lett."},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.brainres.2018.04.016","article-title":"Brain sites mediating cyclosomatostatin-induced catalepsy in Wistar rats: A specific role for the nigrostriatal system and locus coeruleus","volume":"1691","author":"Ionov","year":"2018","journal-title":"Brain Res."},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.brainresbull.2020.03.013","article-title":"Cyclosomatostatin-induced catalepsy in aged rats: Specific change of brain c-Fos protein expression in the lateral entorhinal cortex","volume":"159","author":"Ionov","year":"2020","journal-title":"Brain Res. Bull."},{"key":"ref_458","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1540\/jsmr.56.69","article-title":"The inhibitory effect of somatostatin on gastric motility in Suncus murinus","volume":"56","author":"Sekiya","year":"2020","journal-title":"J. Smooth Muscle Res."},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1007\/s00213-021-05870-3","article-title":"Anticataleptic activity of nicotine in rats: Involvement of the lateral entorhinal cortex","volume":"238","author":"Ionov","year":"2021","journal-title":"Psychopharmacology"},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"101166","DOI":"10.1016\/j.molmet.2021.101166","article-title":"Free fatty acid receptor 4 inhibitory signaling in delta cells regulates islet hormone secretion in mice","volume":"45","author":"Croze","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_461","doi-asserted-by":"crossref","unstructured":"Hernandez-Unzueta, I., Benedicto, A., Telleria, U., Sanz, E., and M\u00e1rquez, J. (2023). Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer. Nutrients, 15.","DOI":"10.3390\/nu15112536"},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: Progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: Traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_464","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.regpep.2009.09.006","article-title":"Novel, non-peptidic somatostatin receptor subtype 5 antagonists improve glucose tolerance in rodents","volume":"159","author":"Sprecher","year":"2010","journal-title":"Regul. Pept."},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1016\/j.bmc.2017.06.007","article-title":"Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus","volume":"25","author":"Hirose","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"ref_466","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0028-3908(00)00035-6","article-title":"Selective somatostatin sst2 receptor blockade with the novel cyclic octapeptide, CYN-154806","volume":"39","author":"Feniuk","year":"2000","journal-title":"Neuropharmacology"},{"key":"ref_467","doi-asserted-by":"crossref","unstructured":"Takeuchi, K., Endoh, T., Hayashi, S., and Aihara, T. (2016). Activation of Muscarinic Acetylcholine Receptor Subtype 4 Is Essential for Cholinergic Stimulation of Gastric Acid Secretion: Relation to D Cell\/Somatostatin. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00278"},{"key":"ref_468","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1021\/ml300063m","article-title":"The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes","volume":"3","author":"He","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_469","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/jm9806289","article-title":"Highly potent cyclic disulfide antagonists of somatostatin","volume":"42","author":"Hocart","year":"1999","journal-title":"J. Med. Chem."},{"key":"ref_470","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0014-2999(02)01341-9","article-title":"Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists","volume":"438","author":"Rossowski","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_471","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1476-5381.1995.tb15906.x","article-title":"Further evidence from functional studies for somatostatin receptor heterogeneity in guinea-pig isolated ileum, vas deferens and right atrium","volume":"115","author":"Feniuk","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"ref_472","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1021\/acsmedchemlett.8b00305","article-title":"Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition","volume":"9","author":"Liu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_473","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1210\/jc.2002-020934","article-title":"Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells","volume":"87","author":"Saveanu","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_474","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/eje.1.01950","article-title":"Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy","volume":"153","author":"Jaquet","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"ref_475","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity","volume":"288","author":"Rocheville","year":"2000","journal-title":"Science"},{"key":"ref_476","doi-asserted-by":"crossref","unstructured":"Miki, Y. (2023). Hormone-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310830"},{"key":"ref_477","doi-asserted-by":"crossref","first-page":"R10","DOI":"10.1530\/EC-18-0425","article-title":"Therapeutic advances in hormone-dependent cancers: Focus on prostate, breast and ovarian cancers","volume":"8","author":"Ulm","year":"2019","journal-title":"Endocr. Connect."},{"key":"ref_478","doi-asserted-by":"crossref","unstructured":"Emons, G. (2023). Hormone-Dependent Cancers: Molecular Mechanisms and Therapeutical Implications. Cells, 12.","DOI":"10.3390\/cells12010110"},{"key":"ref_479","doi-asserted-by":"crossref","unstructured":"Stueven, A.K., Kayser, A., Wetz, C., Amthauer, H., Wree, A., Tacke, F., Wiedenmann, B., Roderburg, C., and Jann, H. (2019). Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20123049"},{"key":"ref_480","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s00259-016-3527-x","article-title":"High clinical and morphologic response using (90)Y-DOTA-octreotate sequenced with (177)Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours","volume":"44","author":"Kong","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_481","doi-asserted-by":"crossref","unstructured":"Kumar, U. (2023). Somatostatin and Somatostatin Receptors in Tumour Biology. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010436"},{"key":"ref_482","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/17446651.2023.2166488","article-title":"Resistance of neuroendocrine tumours to somatostatin analogs","volume":"18","author":"Angelousi","year":"2023","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_483","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.21037\/jgo-22-1182","article-title":"Real world use of lanreotide in neuroendocrine tumors","volume":"14","author":"Siddiqui","year":"2023","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_484","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/0-306-46832-8_6","article-title":"Somatostatin and opioid receptors in mammary tissue. Role in cancer cell growth","volume":"480","author":"Hatzoglou","year":"2000","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_485","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0009-9236(99)70136-0","article-title":"Dose-dependent gastrointestinal effects of the somatostatin analog lanreotide in healthy volunteers","volume":"65","author":"Drewe","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_486","doi-asserted-by":"crossref","unstructured":"Juliana, C.A., Chai, J., Arroyo, P., Rico-Bautista, E., Betz, S.F., and De Le\u00f3n, D.D. (2023). A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.104816"},{"key":"ref_487","first-page":"e220077","article-title":"The role of serotonin inhibition within the treatment of carcinoid syndrome","volume":"3","author":"George","year":"2023","journal-title":"Endocr. Oncol."},{"key":"ref_488","doi-asserted-by":"crossref","first-page":"17588359221138389","DOI":"10.1177\/17588359221138389","article-title":"Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: Real-world data from the Medical University of Vienna","volume":"14","author":"Melhorn","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_489","doi-asserted-by":"crossref","unstructured":"Caruntu, A., Moraru, L., Surcel, M., Munteanu, A., Costache, D.O., Tanase, C., Constantin, C., Scheau, C., Neagu, M., and Caruntu, C. (2022). Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma. Healthcare, 10.","DOI":"10.3390\/healthcare10020342"},{"key":"ref_490","first-page":"1","article-title":"Signal transduction in T helper cells: CD4 coreceptors exert complex regulatory effects on T cell activation and function","volume":"6","author":"Zhou","year":"2004","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_491","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3390\/cimb43010019","article-title":"Renal Cell Carcinoma-Infiltrating CD3low V\u03b39V\u03b41 T Cells Represent Potentially Novel Anti-Tumor Immune Players","volume":"43","author":"Lee","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_492","first-page":"27","article-title":"Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors","volume":"46","author":"Botero","year":"2023","journal-title":"J. Endocrinol. Investig."},{"key":"ref_493","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1365-2265.1995.tb00535.x","article-title":"Prevalence of Helicobacter pylori in acromegalic patients during treatment with octreotide","volume":"43","author":"Jones","year":"1995","journal-title":"Clin. Endocrinol."},{"key":"ref_494","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2265.1992.tb02315.x","article-title":"Prevalence of gastritis in patients with acromegaly: Untreated and during treatment with octreotide","volume":"37","author":"Anderson","year":"1992","journal-title":"Clin. Endocrinol."},{"key":"ref_495","doi-asserted-by":"crossref","first-page":"174976","DOI":"10.1016\/j.ejphar.2022.174976","article-title":"Octreotide-based therapies effectively protect mice from acute and chronic gastritis","volume":"928","author":"Xu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_496","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-2999(00)00341-1","article-title":"Systemic anti-inflammatory effect of somatostatin released from capsaicin-sensitive vagal and sciatic sensory fibres of the rat and guinea-pig","volume":"399","author":"Helyes","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_497","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0928-4257(01)00023-7","article-title":"Capsaicin-sensitive afferents and their role in gastroprotection: An update","volume":"95","year":"2001","journal-title":"J. Physiol. Paris."},{"key":"ref_498","doi-asserted-by":"crossref","unstructured":"Periferakis, A.T., Periferakis, A., Periferakis, K., Caruntu, A., Badarau, I.A., Savulescu-Fiedler, I., Scheau, C., and Caruntu, C. (2023). Antimicrobial Properties of Capsaicin: Available Data and Future Research Perspectives. Nutrients, 15.","DOI":"10.3390\/nu15194097"},{"key":"ref_499","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.3390\/cimb46080468","article-title":"Capsaicin: Emerging Pharmacological and Therapeutic Insights","volume":"46","author":"Petran","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_500","first-page":"295","article-title":"Neurotoxic effect of capsaicin in mammals","volume":"69","author":"Such","year":"1987","journal-title":"Acta Physiol. Hung."},{"key":"ref_501","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cne.902960310","article-title":"Capsaicin-induced neuronal degeneration in the brain and retina of preweanling rats","volume":"296","author":"Ritter","year":"1990","journal-title":"J. Comp. Neurol."},{"key":"ref_502","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/1040-830491379236","article-title":"Capsaicin and gastric ulcers","volume":"46","author":"Satyanarayana","year":"2006","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_503","doi-asserted-by":"crossref","unstructured":"Georgescu, S.R., S\u00e2rbu, M.I., Matei, C., Ilie, M.A., Caruntu, C., Constantin, C., Neagu, M., and Tampa, M. (2017). Capsaicin: Friend or Foe in Skin Cancer and Other Related Malignancies?. Nutrients, 9.","DOI":"10.3390\/nu9121365"},{"key":"ref_504","doi-asserted-by":"crossref","first-page":"984","DOI":"10.31925\/farmacia.2020.6.4","article-title":"Emerging applications of some important natural compounds in the field of oncology","volume":"68","author":"Scheau","year":"2020","journal-title":"Farmacia"},{"key":"ref_505","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3892\/etm.2021.10349","article-title":"Comparative effects of capsaicin in chronic obstructive pulmonary disease and asthma (Review)","volume":"22","author":"Dumitrache","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_506","doi-asserted-by":"crossref","unstructured":"Popescu, G.D.A., Scheau, C., Badarau, I.A., Dumitrache, M.D., Caruntu, A., Scheau, A.E., Costache, D.O., Costache, R.S., Constantin, C., and Neagu, M. (2020). The Effects of Capsaicin on Gastrointestinal Cancers. Molecules, 26.","DOI":"10.3390\/molecules26010094"},{"key":"ref_507","doi-asserted-by":"crossref","unstructured":"Scheau, C., Badarau, I.A., Caruntu, C., Mihai, G.L., Didilescu, A.C., Constantin, C., and Neagu, M. (2019). Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma. Molecules, 24.","DOI":"10.3390\/molecules24132350"},{"key":"ref_508","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1080\/10408398.2013.772090","article-title":"Biological Activities of Red Pepper (Capsicum annuum) and Its Pungent Principle Capsaicin: A Review","volume":"56","author":"Srinivasan","year":"2016","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"ref_509","doi-asserted-by":"crossref","unstructured":"Bencze, N., Schvarcz, C., Kriszta, G., Danics, L., Sz\u0151ke, \u00c9., Balogh, P., Sz\u00e1ll\u00e1si, \u00c1., Hamar, P., Helyes, Z., and Botz, B. (2021). Desensitization of Capsaicin-Sensitive Afferents Accelerates Early Tumor Growth via Increased Vascular Leakage in a Murine Model of Triple Negative Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.685297"},{"key":"ref_510","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1002\/smll.201600618","article-title":"Somatostatin Receptor-Mediated Tumor-Targeting Nanocarriers Based on Octreotide-PEG Conjugated Nanographene Oxide for Combined Chemo and Photothermal Therapy","volume":"12","author":"Zhang","year":"2016","journal-title":"Small"},{"key":"ref_511","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.semcancer.2019.08.029","article-title":"Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy","volume":"69","author":"Aiello","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_512","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.semcancer.2019.07.023","article-title":"Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects","volume":"69","author":"Khan","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_513","doi-asserted-by":"crossref","unstructured":"Matei, A.-M., Caruntu, C., Tampa, M., Georgescu, S.R., Matei, C., Constantin, M.M., Constantin, T.V., Calina, D., Ciubotaru, D.A., and Badarau, I.A. (2021). Applications of Nanosized-Lipid-Based Drug Delivery Systems in Wound Care. Appl. Sci., 11.","DOI":"10.3390\/app11114915"},{"key":"ref_514","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.semcancer.2022.01.007","article-title":"The development and progress of nanomedicine for esophageal cancer diagnosis and treatment","volume":"86","author":"Li","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_515","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_516","first-page":"20180032","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_517","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/AOG.0000000000001268","article-title":"Acupuncture to Reduce Sleep Disturbances in Perimenopausal and Postmenopausal Women: A Systematic Review and Meta-analysis","volume":"127","author":"Chiu","year":"2016","journal-title":"Obstet. Gynecol."},{"key":"ref_518","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lfs.2018.02.005","article-title":"Effects of acupuncture on the levels of serum estradiol and pituitary estrogen receptor beta in a rat model of induced super ovulation","volume":"197","author":"Fu","year":"2018","journal-title":"Life Sci."},{"key":"ref_519","first-page":"599","article-title":"Acupuncture combined with medication improves endocrine hormone levels and ovarian reserve function in poor ovarian response patients undergoing in vitro fertilization-embryo transplantation","volume":"44","author":"Dong","year":"2019","journal-title":"Zhen Ci Yan Jiu"},{"key":"ref_520","first-page":"6730274","article-title":"Effect of Acupuncture on Simple Obesity and Serum Levels of Prostaglandin E and Leptin in Sprague-Dawley Rats","volume":"2021","author":"Li","year":"2021","journal-title":"Comput. Math. Methods Med."},{"key":"ref_521","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/09645284211056655","article-title":"Effect of acupuncture on menopausal hot flushes and serum hormone levels: A systematic review and meta-analysis","volume":"40","author":"Liu","year":"2022","journal-title":"Acupunct. Med."},{"key":"ref_522","doi-asserted-by":"crossref","first-page":"101541","DOI":"10.1016\/j.ctcp.2022.101541","article-title":"Electroacupuncture and acupuncture in the treatment of anxiety\u2014A double blinded randomized parallel clinical trial","volume":"46","author":"Amorim","year":"2022","journal-title":"Complement. Ther. Clin. Pract."},{"key":"ref_523","first-page":"36","article-title":"Treating gout caused by renal insufficiency with acupuncture and moxibustion: A case report","volume":"6","author":"Periferakis","year":"2023","journal-title":"Rom. J. Clin. Res."},{"key":"ref_524","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.autneu.2010.05.001","article-title":"Acupuncture and cancer","volume":"157","author":"Filshie","year":"2010","journal-title":"Auton. Neurosci."},{"key":"ref_525","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bmjspcare-2020-002638","article-title":"Acupuncture for palliative cancer pain management: Systematic review","volume":"11","author":"Yang","year":"2021","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_526","doi-asserted-by":"crossref","first-page":"154160","DOI":"10.1016\/j.phymed.2022.154160","article-title":"Acupuncture for cancer-related insomnia: A systematic review and meta-analysis","volume":"102","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"key":"ref_527","doi-asserted-by":"crossref","first-page":"154430","DOI":"10.1016\/j.phymed.2022.154430","article-title":"Acupuncture for cancer-related conditions: An overview of systematic reviews","volume":"106","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"key":"ref_528","first-page":"290","article-title":"The role of substance P and somatostatin in acupuncture and moxibustion-induced postsynaptic inhibition","volume":"18","author":"Zhu","year":"1993","journal-title":"Zhen Ci Yan Jiu"},{"key":"ref_529","first-page":"G524","article-title":"Inhibition of acid secretion by electrical acupuncture is mediated via beta-endorphin and somatostatin","volume":"271","author":"Jin","year":"1996","journal-title":"Am. J. Physiol."},{"key":"ref_530","first-page":"474","article-title":"Somatostatin and electroacupuncture inhibited c-fos expression in spinal cord of arthritic rats","volume":"18","author":"Ruan","year":"1997","journal-title":"Zhongguo Yao Li Xue Bao"},{"key":"ref_531","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3748\/wjg.v13.i15.2229","article-title":"Effect of acupuncture at Foot-Yangming Meridian on gastric mucosal blood flow, gastric motility and brain-gut peptide","volume":"13","author":"Lin","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_532","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11655-011-0795-y","article-title":"Effect of electro-acupuncture at different acupoints on neuropeptide and somatostatin in rat brain with irritable bowel syndrome","volume":"18","author":"Zhu","year":"2012","journal-title":"Chin. J. Integr. Med."},{"key":"ref_533","first-page":"363","article-title":"Effect of acupuncture at \u201cZusanli\u201d (ST 36 and \u201cTaichong\u201d (LR 3) on gastrointestinal hormone levels in rats with diarrhea type irritable bowel syndrome","volume":"37","author":"Liu","year":"2012","journal-title":"Zhen Ci Yan Jiu"},{"key":"ref_534","first-page":"98","article-title":"Effects of electroacupuncture on plasma and cerebral somatostatin and beta-EP contents and learning-memory ability in vascular dementia rats","volume":"33","author":"Shao","year":"2008","journal-title":"Zhen Ci Yan Jiu"},{"key":"ref_535","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12031-012-9843-0","article-title":"Effects of Zusanli electroacupuncture on somatostatin expression in the rat brainstem","volume":"49","author":"Tian","year":"2013","journal-title":"J. Mol. Neurosci."},{"key":"ref_536","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3748\/wjg.v12.i11.1761","article-title":"Effect of electro-acupuncture at Foot-Yangming Meridian on somatostatin and expression of somatostatin receptor genes in rabbits with gastric ulcer","volume":"12","author":"Yi","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"ref_537","first-page":"54","article-title":"Effects of electro-acupuncture on somatostatin and pancreatic polypeptide in ischemic cerebrovascular diseases","volume":"19","author":"Zhang","year":"1999","journal-title":"J. Tradit. Chin. Med."},{"key":"ref_538","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3736\/jcim20100706","article-title":"Effects of moxibustion at head-points on levels of somatostatin and arginine vasopressin from cerebrospinal fluid in patients with vascular dementia: A randomized controlled trial","volume":"8","author":"Wang","year":"2010","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"ref_539","first-page":"22","article-title":"Expression of somatostatin mRNA and coexistence of SOM mRNA and 5-HT in nucleus raphe dorsalis following noxious stimulation and electroacupuncture analgesia","volume":"21","author":"Fang","year":"1996","journal-title":"Zhen Ci Yan Jiu"},{"key":"ref_540","first-page":"307","article-title":"Effect of somatostatin on functions of acupuncture meridians","volume":"36","author":"Guo","year":"2011","journal-title":"Zhen Ci Yan Jiu"},{"key":"ref_541","doi-asserted-by":"crossref","first-page":"37","DOI":"10.11152\/mu-1705","article-title":"MRI-TRUS fusion guided prostate biopsy\u2014Initial experience and assessment of the role of contralateral lobe systematic biopsy","volume":"21","author":"Andras","year":"2019","journal-title":"Med. Ultrason."},{"key":"ref_542","first-page":"145","article-title":"MRI-targeted prostate biopsy: The next step forward!","volume":"94","author":"Cata","year":"2021","journal-title":"Med. Pharm. Rep."},{"key":"ref_543","doi-asserted-by":"crossref","unstructured":"Malik, D., Pant, V., Sen, I., Thakral, P., Das, S.S., and Cb, V. (2023). The Role of PET-CT-Guided Metabolic Biopsies in Improving Yield of Inconclusive Anatomical Biopsies: A Review of 5 Years in a Teaching Hospital. Diagnostics, 13.","DOI":"10.3390\/diagnostics13132221"},{"key":"ref_544","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40644-019-0253-1","article-title":"PET\/CT-guided versus CT-guided percutaneous core biopsies in the diagnosis of bone tumors and tumor-like lesions: Which is the better choice?","volume":"19","author":"Wu","year":"2019","journal-title":"Cancer Imaging"},{"key":"ref_545","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2967\/jnumed.120.252403","article-title":"PET\/CT-guided biopsy of suspected lung lesions requires less rebiopsy than CT-guided biopsy due to inconclusive results","volume":"62","author":"Cerci","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_546","first-page":"206","article-title":"Updates in MRI characterization of the thymus in myasthenic patients","volume":"5","author":"Popa","year":"2012","journal-title":"J. Med. Life"},{"key":"ref_547","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.7150\/jca.30240","article-title":"Comparison between CT and MRI in the Diagnostic Accuracy of Thymic Masses","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"key":"ref_548","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1158\/1078-0432.CCR-18-3312","article-title":"Specific Targeting of Somatostatin Receptor Subtype-2 for Fluorescence-Guided Surgery","volume":"25","author":"Kossatz","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_549","doi-asserted-by":"crossref","unstructured":"Dragosloveanu, S., Petre, M.A., Gherghe, M.E., Nedelea, D.G., Scheau, C., and Cergan, R. (2023). Overall Accuracy of Radiological Digital Planning for Total Hip Arthroplasty in a Specialized Orthopaedics Hospital. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134503"},{"key":"ref_550","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.2967\/jnumed.115.161158","article-title":"Radiopeptides for Imaging and Therapy: A Radiant Future","volume":"56","author":"Chatalic","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_551","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.semnuclmed.2022.12.007","article-title":"Molecular imaging Theranostics of Neuroendocrine Tumors","volume":"53","author":"Fortunati","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_552","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2019.3.FOCUS1925","article-title":"Impact of 68Ga-DOTATOC PET\/MRI on robotic radiosurgery treatment planning in meningioma patients: First experiences in a single institution","volume":"46","author":"Acker","year":"2019","journal-title":"Neurosurg. Focus"},{"key":"ref_553","doi-asserted-by":"crossref","unstructured":"Dragosloveanu, S., Petre, M.A., Capitanu, B.S., Dragosloveanu, C.D.M., Cergan, R., and Scheau, C. (2023). Initial Learning Curve for Robot-Assisted Total Knee Arthroplasty in a Dedicated Orthopedics Center. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216950"},{"key":"ref_554","doi-asserted-by":"crossref","unstructured":"Wang, W., Deng, J., Li, H., Ji, Z., and Wen, J. (2023). Laparoscopic resection of a paraganglioma behind the retrohepatic segment of the inferior vena cava: A case report and literature review. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1171045"},{"key":"ref_555","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1530\/ERC-19-0086","article-title":"Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors","volume":"26","author":"Culler","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_556","doi-asserted-by":"crossref","unstructured":"Timofticiuc, I.A., C\u0103linescu, O., Iftime, A., Dragosloveanu, S., Caruntu, A., Scheau, A.E., Badarau, I.A., Didilescu, A.C., Caruntu, C., and Scheau, C. (2023). Biomaterials Adapted to Vat Photopolymerization in 3D Printing: Characteristics and Medical Applications. J. Funct. Biomater., 15.","DOI":"10.3390\/jfb15010007"},{"key":"ref_557","doi-asserted-by":"crossref","unstructured":"Periferakis, A., Periferakis, A.T., Troumpata, L., Dragosloveanu, S., Timofticiuc, I.A., Georgatos-Garcia, S., Scheau, A.E., Periferakis, K., Caruntu, A., and Badarau, I.A. (2024). Use of Biomaterials in 3D Printing as a Solution to Microbial Infections in Arthroplasty and Osseous Reconstruction. Biomimetics, 9.","DOI":"10.3390\/biomimetics9030154"},{"key":"ref_558","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1\u20135 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Xu","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_559","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5603\/NMR.2016.0022","article-title":"Neuroendocrine neoplasms and somatostatin receptor subtypes expression","volume":"19","author":"Hankus","year":"2016","journal-title":"Nucl. Med. Rev. Cent. East. Eur."},{"key":"ref_560","doi-asserted-by":"crossref","first-page":"33174","DOI":"10.1074\/jbc.273.50.33174","article-title":"Somatostatin receptor desensitization in NG108-15 cells. A consequence of receptor sequestration","volume":"273","author":"Beaumont","year":"1998","journal-title":"J. Biol. Chem."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/9\/578\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:47:10Z","timestamp":1760111230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/46\/9\/578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":560,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["cimb46090578"],"URL":"https:\/\/doi.org\/10.3390\/cimb46090578","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}